Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Published: September 2016
No. of Pages: 73
    ReportsandReports

Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is the most common and aggressive human brain tumor, accounting for 15.4% of all primary brain tumors and 60-75% of all astrocytomas. It has a peak incidence between 55 and 84 years of age, with the median age of diagnosis being 64 years. In the US and EU, the annual incidence was estimated to be three to four cases per 100,000 people. GBM has a high degree of intratumoral heterogeneity, which is associated with poor prognosis and the development of drug resistance.

The GBM market is characterized by a small selection of marketed product options, consisting of chemotherapies, cancer immunotherapies and receptor tyrosine kinase inhibitor products. The pipeline is moderately large, with 512 products active across all stages of development. First-in-class products only constitute approximately a quarter of the pipeline, and represent 31% of products with a disclosed target. The most widely studied group of first-in-class targets are the receptor tyrosine kinase and ligand inhibitors, a trend that has been heavily influenced by the success of Avastin, and possibly successful EGFR inhibitors such as Tarceva that are used in the treatment of other oncology indications.

Potential driving factors for the market include a typically poor outcome for treated patients, a growing patient pool if disease prognosis can be improved, a lack of approved options in the market, and a strong understanding of the disease pathophysiology that has developed over the last decade, facilitating the development of novel compounds that may fulfill the unmet needs.

Overall, due to the highly complex and polygenic nature of GBM, which has numerous subtype classifications, it is unlikely that the inhibition of a single target will be sufficient to substantially improve patient prognosis. Instead, it is more likely that the concurrent use of multiple targeted therapies, along with other available modes of therapy, may improve treatment outcomes. First-in-class targets analyzed in this report have shown encouraging efficacy profiles, and some show the ability to chemosensitize cancer cells.

Scope

  • The report analyzes innovation in GBM, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products, and pinpoints opportunities for in-licensing.
  • A brief introduction to GBM, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms.
  • The changing molecular target landscape between the market and the pipeline, including particular focal points of innovation in the pipeline.
  • A comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.
  • Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.
  • Assessment of the licensing and co-development deal landscape for GBM therapies.

Reasons to buy

  • Understand the current clinical and commercial landscape, including a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options.
  • Visualize the composition of the GBM market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of the gaps in the current market.
  • Analyze the GBM pipeline, stratified by stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
  • Identify commercial opportunities in the GBM deals landscape by analyzing trends in licensing and co-development deals.

Published By: GBI Research
Product Code: GBI Research1570


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:

  • China Cefazolin Sodium Market Research Report 2017

    Notes: Sales, means the sales volume of Cefazolin Sodium Revenue, means the sales value of Cefazolin Sodium This report studies Cefazolin Sodium in China market, focuses on the top players in China market, with capacity, production, price, reven...

  • China Artemisinin Market Research Report 2017

    Notes: Sales, means the sales volume of Artemisinin Revenue, means the sales value of Artemisinin This report studies Artemisinin in China market, focuses on the top players in China market, with capacity, production, price, revenue and market s...

  • China Animal Gelatin Capsules Market Research Report 2017

    Notes: Sales, means the sales volume of Animal Gelatin Capsules Revenue, means the sales value of Animal Gelatin Capsules This report studies Animal Gelatin Capsules in China market, focuses on the top players in China market, with capacity, pro...

  • China Animal Free Soft Gelatin Capsules Market Research Report 2017

    Notes: Sales, means the sales volume of Animal Free Soft Gelatin Capsules Revenue, means the sales value of Animal Free Soft Gelatin Capsules This report studies Animal Free Soft Gelatin Capsules in China market, focuses on the top players in Ch...

  • Europe Generic Drugs Market Report 2017

    Notes: Sales, means the sales volume of Generic Drugs Revenue, means the sales value of Generic Drugs This report studies sales (consumption) of Generic Drugs in Europe market, especially in Germany, France, UK, Russia, Italy, Spain and Benelux,...

  • Europe Fractionated Fatty Acid Market Report 2017

    Notes: Sales, means the sales volume of Fractionated Fatty Acid Revenue, means the sales value of Fractionated Fatty Acid This report studies sales (consumption) of Fractionated Fatty Acid in Europe market, especially in Germany, France, UK, Rus...

  • Europe Esomeprazole Market Report 2017

    Notes: Sales, means the sales volume of Esomeprazole Revenue, means the sales value of Esomeprazole This report studies sales (consumption) of Esomeprazole in Europe market, especially in Germany, France, UK, Russia, Italy, Spain and Benelux, fo...

  • Europe Drugs for Osteoarthritis Pain Market Report 2017

    Notes: Sales, means the sales volume of Drugs for Osteoarthritis Pain Revenue, means the sales value of Drugs for Osteoarthritis Pain This report studies sales (consumption) of Drugs for Osteoarthritis Pain in Europe market, especially in German...

  • United States Powdered Gloves Market Report 2017

    Notes: Sales, means the sales volume of Powdered Gloves Revenue, means the sales value of Powdered Gloves This report studies sales (consumption) of Powdered Gloves in United States market, focuses on the top players, with sales, price, revenue ...

  • United States Poultry Chlortetracycline Market Report 2017

    Notes: Sales, means the sales volume of Poultry Chlortetracycline Revenue, means the sales value of Poultry Chlortetracycline This report studies sales (consumption) of Poultry Chlortetracycline in United States market, focuses on the top player...


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: